Overview

Efficacy of an Encapsulated Probiotic Bifidobacterium Infantis 35624 in Irritable Bowel Syndrome

Status:
Completed
Trial end date:
2004-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to determine the dose-ranging efficacy and safety profile of encapsulated Bifidobacterium infantis 35624 in female subjects with irritable bowel syndrome (IBS).
Phase:
Phase 3
Details
Lead Sponsor:
Procter and Gamble
Collaborator:
Alimentary Health Ltd